Outlook Therapeutics, Inc. (OTLK) CEO Buys $22,500.00 in Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO Lawrence A. Kenyon acquired 25,000 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was acquired at an average cost of $0.90 per share, for a total transaction of $22,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

OTLK stock opened at $0.92 on Monday. Outlook Therapeutics, Inc. has a 12-month low of $0.20 and a 12-month high of $0.98.

Separately, ValuEngine cut Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://transcriptdaily.com/2019/02/11/outlook-therapeutics-inc-otlk-ceo-buys-22500-00-in-stock.html.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Insider Buying and Selling by Quarter for Outlook Therapeutics (NASDAQ:OTLK)

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply